Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein
- PMID: 15967544
- DOI: 10.1016/j.vaccine.2005.04.041
Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein
Abstract
In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/neu receptor (ECDHER2) plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/neu. Immune effectors including CD4+, CD8+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens.
Similar articles
-
Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.Vaccine. 2006 Jan 16;24(3):304-16. doi: 10.1016/j.vaccine.2005.07.073. Epub 2005 Aug 10. Vaccine. 2006. PMID: 16125282
-
Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.Mol Immunol. 2006 Feb;43(6):667-76. doi: 10.1016/j.molimm.2005.04.007. Mol Immunol. 2006. PMID: 15908002
-
Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.Cancer Gene Ther. 2007 Nov;14(11):904-17. doi: 10.1038/sj.cgt.7701081. Epub 2007 Aug 17. Cancer Gene Ther. 2007. PMID: 17704754
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
HER-2/neu as a target for cancer vaccines.Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Immunotherapy. 2010. PMID: 20635929 Review.
Cited by
-
Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.J Control Release. 2013 Nov 10;171(3):322-9. doi: 10.1016/j.jconrel.2013.06.001. Epub 2013 Jun 12. J Control Release. 2013. PMID: 23770212 Free PMC article.
-
4H12, a Murine Monoclonal Antibody Directed against Myosin Heavy Chain-9 Expressed on Acinar Cell Carcinoma of Pancreas with Potential Therapeutic Application.Iran Biomed J. 2021 Sep 1;25(5):310-22. doi: 10.52547/ibj.25.5.310. Iran Biomed J. 2021. PMID: 34425650 Free PMC article.
-
Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.Cell Stress Chaperones. 2010 Nov;15(6):977-84. doi: 10.1007/s12192-010-0208-8. Epub 2010 Jun 12. Cell Stress Chaperones. 2010. PMID: 20544406 Free PMC article.
-
Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.Cell Stress Chaperones. 2011 Jul;16(4):449-57. doi: 10.1007/s12192-011-0258-6. Epub 2011 Feb 26. Cell Stress Chaperones. 2011. PMID: 21359667 Free PMC article.
-
Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.Cancer Immunol Immunother. 2007 Sep;56(9):1507-12. doi: 10.1007/s00262-007-0297-0. Epub 2007 Feb 20. Cancer Immunol Immunother. 2007. PMID: 17310381 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous